CN1349812A - Medicinal composition for treating myocardial diseases and preparation process thereof - Google Patents
Medicinal composition for treating myocardial diseases and preparation process thereof Download PDFInfo
- Publication number
- CN1349812A CN1349812A CN00131516A CN00131516A CN1349812A CN 1349812 A CN1349812 A CN 1349812A CN 00131516 A CN00131516 A CN 00131516A CN 00131516 A CN00131516 A CN 00131516A CN 1349812 A CN1349812 A CN 1349812A
- Authority
- CN
- China
- Prior art keywords
- treatment
- cardiomyopathy
- myrrha
- olibanum
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031229 Cardiomyopathies Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title description 7
- 238000011282 treatment Methods 0.000 claims abstract description 51
- 239000004863 Frankincense Substances 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 14
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000000341 volatile oil Substances 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 6
- 238000000227 grinding Methods 0.000 claims abstract description 4
- 238000012545 processing Methods 0.000 claims abstract description 3
- 238000005516 engineering process Methods 0.000 claims description 16
- 241000717739 Boswellia sacra Species 0.000 claims description 15
- 241001057584 Myrrha Species 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 12
- 241001489978 Eupolyphaga Species 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 206010047470 viral myocarditis Diseases 0.000 abstract description 4
- 230000003680 myocardial damage Effects 0.000 abstract description 3
- 230000002107 myocardial effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 230000003915 cell function Effects 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 230000000451 tissue damage Effects 0.000 abstract description 2
- 231100000827 tissue damage Toxicity 0.000 abstract description 2
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 2
- 240000007551 Boswellia serrata Species 0.000 abstract 2
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 2
- 241000131329 Carabidae Species 0.000 abstract 2
- 240000007311 Commiphora myrrha Species 0.000 abstract 2
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 2
- 241000402754 Erythranthe moschata Species 0.000 abstract 2
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052683 pyrite Inorganic materials 0.000 abstract 1
- 239000011028 pyrite Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000049 pigment Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 5
- 206010011703 Cyanosis Diseases 0.000 description 5
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 5
- 208000009525 Myocarditis Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000012949 viral dilated cardiomyopathy Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine, in particular to a pharmaceutical composition for treating myocardial diseases and a preparation process thereof. Is prepared from notoginseng, musk, American ginseng, frankincense, myrrh, ground beetle, dragon's bone, pyrite, etc through extracting volatile oil from frankincense and myrrh, collecting, processing, collecting the liquid extract of ground beetle, filtering, concentrating, grinding musk, and mixing with refined notoginseng and American ginseng powder. The invention combines the methods of supplementing qi and nourishing yin, strengthening body resistance and eliminating evil and the like for treating viral myocarditis with the methods of promoting blood circulation and promoting tissue regeneration, treating stasis and dredging collaterals for treating myocardial damage, can improve microcirculation, repair tissue damage, stabilize cell function, resist lipid oxidation and promote the functional recovery of abnormal myocardial cells, has reasonable formula ratio and obvious curative effect, and has good treatment and protection effects on myocardial diseases. The preparation process is short and simple.
Description
The present invention relates to field of medicaments, especially a kind of pharmaceutical composition and preparation technology thereof who treats cardiomyopathy.
According to researching and analysing, in numerous heart disease patient, the viral myocarditis patient occupies the ratio of quite a few, and the trend that rises is day by day arranged, and its clinical manifestation weight differs, and heart failure can appear in weight person, seriously arrhythmia can occur, even sudden death.And its state of an illness is a DCM (dilated cardiomyopathy) at latency development also, and great majority are dead in 5 years subsequently.According to Abelman report, 0.71% cardiac death is arranged owing to the primary cardiac disease in the U.S., and in whole primary cardiac diseases, DCM (dilated cardiomyopathy) accounts for 90%.At present, still lack both at home and abroad the medicine of better curative effect for the treatment of primary disease, still adopt mostly up-to-date immunosuppressant and and treatment means such as interferon; Domestic among the people to have with Radix Panacis Quinquefolii, Moschus, Radix Notoginseng be the myocarditic report of composition treatment by Chinese herbs, but also do not find the preferable formulation components of curative effect, and its preparation technology also remains further research.With modern medicine the degree of concern of hypertension, coronary heart disease is compared with the research dynamics, to myocarditis and the myocardiac research degree of depth, awareness, prevent and treat method and aspects such as long term follow-up and preventive measure also exist very big gap.
The object of the present invention is to provide a kind of from muscle-derived damage, promote injury repairing myocyte functional rehabilitation, reasonable component formula, the curative effect pharmaceutical composition of treatment by Chinese herbs cardiomyopathy preferably.
Another object of the present invention is to provide the preparation of drug combination technology of the described treatment cardiomyopathy that a kind of technology is simple, flow process short, the effective ingredient extraction ratio is high.
Purpose of the present invention can realize by following measure:
A kind of pharmaceutical composition for the treatment of cardiomyopathy is to form by following components in weight percentage: Radix Notoginseng 35-40% Moschus 1-2% Radix Panacis Quinquefolii 15-20% Olibanum 8-12%
Myrrha 8-12% Eupolyphaga Seu Steleophaga 8-12% Os Draconis 8-12% Pyritum 8-12%
Its preparation technology contains following steps:＜1〉extract the volatile oil of Olibanum, Myrrha, and fix with β-CD inclusion, collect post-treatment and become extractum standby;＜2〉preparation Eupolyphaga Seu Steleophaga extracting solution is collected the percolate post-treatment and is become extractum standby;＜3〉the Os Draconis water soluble ingredient is repeatedly taken and filters, reconcentration becomes extractum standby;＜4〉preparation nature powdered copper concentrate;＜5〉Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.Obtained mixture can make capsule through the granulation of sieving, dry in the shade, granulate, plug-in mounting.
Described Olibanum, Myrrha extraction process are as follows: Olibanum, Myrrha are ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that volatilizees again in the water-bath ventilating kitchen with petroleum ether, promptly get volatile oil, mixed inclusion with β-CD again and fix; The processing technique of described Pyritum is: get Pyritum and place inherent being fired to more than 560 ℃ of crucible to be popular in, quench shortcake once in the impouring rice vinegar immediately then, each about 2 hours for several times so repeatedly, until the gloss complete obiteration, airing was placed on and adds water in the mortar repeatedly and be ground to impalpable powder and use again.
The present invention has following advantage compared to existing technology:
The present invention understands systematicly myocarditis and myocardiac Chinese medicine again from this new visual field of myocardial damage and angle comprehensively, to treat the supplementing QI and nourishing YIN of viral myocarditis, methods and the promoting blood circulation for tissue regeneration for the treatment of the cardiac muscle damage such as strengthening vital QI to eliminate pathogenic factors, control the blood stasis and smoothing collaterals method and combine, but microcirculation improvement, the repair tissue damage, the stabilized cell function, the oxidation of lipotropism matter, promote parafunctional myocardial cell functional rehabilitation, and can transfer the fat the turbid descending, improve cell viability and ion and normally shift distribution, to free radical damage, cardiac muscle is to pressing down myocardial hibernation, non-hat metabolic cardiac damage, the cardiac muscle excitation contraction coupling, situations such as apoptosis all have some improvement.Prescription reasonable mixture ratio of the present invention is evident in efficacy.Cardiomyopathy there are good curing and protective action.
Preparation technology's uniqueness of the present invention, the two lifting manipulations of pharmaceutically active ingredient are extracted in will adopting the volatile oil in the Olibanum Myrrha in the component, and it is consummate in order to active ingredient with the inclusion method, thereby reduce the gastrointestinal tract pessimal stimulation, alleviate or eliminate the untoward reaction of medicine, strengthen drug effect and curative effect, pure product fine powder is utilized not damage curative effect, do not pollute, and with not insulting physico-chemical method to component in addition sterilization handle, utilize above-mentioned prepared Pyritum, make its trace element component help human body and curative effect performance thereof, water solublity such as Os Draconis are extracted composition be condensed into extractum, make capsule again, guaranteed medicine quality and curative effect.
Drug effect theory of the present invention is as follows:
Radix Panacis Quinquefolii in the component of the present invention has the effect of YIN nourishing and the production of body fluid promoting, can be used for deficiency of both QI and YIN, the medical treatment of the disease of consumption of YIN caused by febrile disease; Radix Notoginseng has blood circulation promoting and blood stasis dispelling, the treating blood disorders of enriching blood hemostasis, anti-inflammatory analgesic, the effect of strengthening by means of tonics defying age, be used for physical weakness, insufficiency of vital energy and blood, is mended through weak better effect is arranged dizziness and blurred vision, and combinations such as Eupolyphaga Seu Steleophaga, Moschus, Os Draconis have the effect of blood circulation and promoting silt tissue regeneration promoting detumescence, can recuperate under medical treatment in the cardiac muscle damage.
Maximum tolerance determination result of the present invention is as follows:
20 of mices, male and female half and half, disposable ig60% suspension 0.4ml/10g of the present invention (animal capable tolerates the dose of Cmax and maximum volume), observe the mice active situation then and have or not death, continue 7 days, find that the mice ordinary circumstance is good, feed is normal, fur is bright and clean, and so none dead mouse is Ld
50Can't measure; Its maximum tolerated dose is 24g/kg, is equivalent to about 400 times of clinical application amount, is very safe so the present invention uses.
The present invention is through clinical use treatment myocarditis and dilated cardiomyopathy checking, and the result is as follows:
Viral myocarditis and dilated cardiomyopathy group patient amount to 77 examples, man's 22 examples, woman's 55 examples, myocarditis 65 examples, cardiomyopathy 12 examples, serious symptom person's 17 examples, middle disease person 59 examples, light disease person 1 example, through the present invention's treatment, observe cardiopalmus, uncomfortable in chest, chest pain, breathe hard, the degree of seven symptoms before and after treatment such as weak, cyanosis, edema with lapse to.Wherein the severity of symptom branch attach most importance to (+++), in (++), light (+), do not have (-) grade, its result such as following table:
Before and after the treatment of myocarditis and qtd of cardiomyopathy group symptom integral lapse to comparative observation by stages the cardiopalmus feeling of oppression and pain in the chest breathe hard
++++++-++++++-++++++-++++++-0.00 28.57 24.68 46.75 0.00 25.97 14.29 59.74 0.00 25.97 11.69 62.34 0.00 29.87 24.68 45.45 continued is observed by stages weak cyanosis edema around treating in front one all two three weeks 0.00 32.48 33.76 0.00 0.00 28.58 25.97 45.45 0.00 27.27 19.48 53.25 0.00 28.57 40.26 31.17 of 0.00 45.36 41.56 12.99 0.00 32.47 40.26 27.27 0.00 32 47 27.27 40.46 0.00 42.86 45.45 11.69 treatment week of 2.60 57.14 36.36 3.90 2.60 46.75 44.16 6.49 0.00 44.16 37.66 18.18 3.90 58.44 27.27 10.39 treatments of 25.97 70.13 3.90 0.00 23.38 63.63 12.99 0.00 7.79 57.15 19.48 15.58 36.36 63.64 0.00 0.00 treatments for the treatment of
++++++-++++++-++++++-front 42.86 51.95 5.19 0.00 12.99 40.26 29.87 16.88 14.29 36.36 36.36 12.99 treatments for the treatment of one week, 7.79 59.74 28.57 3.90 6.49 33.77 27.27 32.47 3.90 35.06 22.08 38.96 treatments, two weeks, 1.30 50.65 29.87 18.18 1.30 38.96 16.88 42.86 0.00 33.76 12.99 53.25 treatments, three week 0.00 36.36 32.47 31.17 0.00 33.77 16.88 49.35 0.00 35.06 10.39 54.55 treatments all around 0.00 32.47 25.97 41.56 0.00 29.87 15.58 54.55 0.00 32.47 6.49 61.04
After with the present invention 4 week treatment, cardiopalmus, uncomfortable in chest, chest pain, breathe hard, seven symptoms such as weak, cyanosis, edema obviously reduce, produce effects person's 25 examples after the statistical result, responder's 52 examples, total effective rate reaches 100%.And after the treatment, the contrast myocardial enzymes the analysis showed that, shows that index lactic acid dehydrogenase (LDH), creatine phosphokinase (CK), the glutamic oxaloacetic transaminase, GOT (GOT) of myocardial damage all has obvious reduction; In addition, Liver and kidney merit and change of blood sugar and routine blood test change contrast before and after the treatment after measured, and the present invention is to Liver and kidney merit and blood glucose and pigment (Hb) total white blood cells and classify and all have no adverse effects.
For investigating the therapeutic effect of the present invention to myocardial ischemia (coronary heart disease), compare through clinical treatment and with commercially available tea pigment capsule and XUESHUANXINMAINING therapeutic effect and to do contrast, wherein of the present invention group of 57 examples, tea pigment capsule group 41 examples, XUESHUANXINMAINING group 38 examples, still observe cardiopalmus, uncomfortable in chest, chest pain, breathe hard, weak, cyanosis, the degree of seven symptoms such as edema before and after treatment with lapse to (%) (%) uncomfortable in chest weak (%) chest pain (%) cyanosis (%) edema (%) treatment preceding 1 57 116 (100) 127 (100) 126 (100) 129 (100) 75 (100) 88 (100) 93 (100) of breathing hard of result such as following table (of the present invention group of 2-tea pigment capsule of 1-group 3-XUESHUANXINMAINING group) the group n cardiopalmus course of treatment (%)
2 41 85(100) 92(100) 92(100) 99(100) 48(100) 60(100) 57(100)
One week 1 57 83 (71.55) 89 (70.08) 80 (63.49) 104 (80.62) 35 (46.67) 67 (76.14) 64 (68.82) of 3 38 94 (100) 65 (100) 66 (100) 84 (100) 55 (100) 43 (100) 56 (100) treatments
2 41 74(87.06)?65(70.65)?59(64.13)?79(79.80)?35(72.91)?55(91.67)?49(85.96)
Two weeks 1 57 56 (48.28) 76 (59.84) 60 (47.62) 87 (73.44) 28 (37.33) 50 (56.82) 41 (44.09) of 3 38 73 (77.66) 45 (69.23) 42 (63.64) 69 (82.14) 38 (64.09) 37 (86.05) 41 (73.21) treatments
2 41 53(62.35)?68(73.91)?61(66.30)?84(84.85)?23(47.92)?44(73.33)?33(57.89)
Three weeks 1 57 41 (35.34) 53 (41.73) 41 (32.54) 70 (54.26) 13 (17.33) 36 (40.91) 27 (29.03) of 3 38 57 (60.64) 41 (64.61) 34 (51.51) 59 (70.24) 27 (49.04) 33 (76.74) 32 (57.14) treatments
2 41 40(47.06)?59(64.13)?46(50.00)?65(65.66)?12(25.00)?29(48.33)?25(43.86)
3 38 39 (41.49) 32 (50.00) 25 (37.88) 51 (60.71) 15 (27.27) 26 (60.47) 22 (39.29) treatment around 1 57 23 (19.83) 30 (23.62) 22 (17.46) 53 (41.08) 8 (10.67) 27 (30.68) 15 (16.13)
2 41 27(31.76)?44(47.83)?30(32.61)?60(60.61)?6(12.50) 26(43.33)?19(33.33)
3 38 31 (32.98) 19 (29.23) 15 (22.72) 44 (52.38) 11 (20.00) 19 (44.19) 14 (25.00) the present invention and Tea Pigment, XUESHUANXINMAINING efficacy result be of the present invention group of 57.89% (33) 38.60% (22) 3.51% (2) 96.49% (55) Tea Pigment group of group produce effects enabledisable total effective rate 26.83% (11) 63.41% (26) 9.76% (4) 90.24% (37) XUESHUANXINMAINING group 42.11% (16) 50.00% (19) 7.89% (3) 92.11% (35) relatively
The result shows that of the present invention group of effective percentage is higher than tea pigment capsule group and XUESHUANXINMAINING group, and inefficiency is also lower, i.e. the present invention has therapeutical effect preferably.
The present invention also will be further described in conjunction with the embodiments:
One one kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment are to form by following components in weight percentage: Radix Notoginseng 35% Moschus 1% Radix Panacis Quinquefolii 19% Olibanum 9%
Myrrha 9% Eupolyphaga Seu Steleophaga 8% Os Draconis 11% Pyritum 8%
Its preparation technology is:＜1〉will get described group component Olibanum, Myrrha is ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that in the water-bath ventilating kitchen, volatilizees again with petroleum ether, promptly get volatile oil, mixed inclusion with β-CD again and fix, collect post-treatment and become extractum standby;＜2〉get described group component Eupolyphaga Seu Steleophaga and prepare extracting solution, collect post-treatment and become extractum standby;＜3〉will get water soluble ingredients such as described group component Os Draconis and repeatedly take and filter, reconcentration becomes extractum standby;＜4〉getting described group component Pyritum places inherent being fired to more than 560 ℃ of crucible to be popular in, quench shortcake once in the impouring rice vinegar immediately then, each about 2 hours for several times so repeatedly, until the gloss complete obiteration, airing was placed on and adds water in the mortar repeatedly and be ground to the impalpable powder degree and use again;＜5〉Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.Obtained mixture can make capsule through the granulation of sieving, dry in the shade, granulate, plug-in mounting.
21 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment, be to form by following components in weight percentage: 9% its preparation technology is identical with embodiment one for Radix Notoginseng 39% Moschus 1% Radix Panacis Quinquefolii 16% Olibanum 8% Myrrha 10% Eupolyphaga Seu Steleophaga 9% Os Draconis 8% Pyritum.
31 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment, be to form by following components in weight percentage: 8% its preparation technology is identical with embodiment one for Radix Notoginseng 36% Moschus 2% Radix Panacis Quinquefolii 18% Olibanum 9% Myrrha 8% Eupolyphaga Seu Steleophaga 10% Os Draconis 9% Pyritum.
41 kinds of pharmaceutical compositions for the treatment of cardiomyopathy of embodiment, be to form by following components in weight percentage: 10% its preparation technology is identical with embodiment one for Radix Notoginseng 37% Moschus 2% Radix Panacis Quinquefolii 17% Olibanum 8% Myrrha 9% Eupolyphaga Seu Steleophaga 8% Os Draconis 9% Pyritum.
The pharmaceutical composition of embodiment kind on May Day treatment cardiomyopathy, be to form by following components in weight percentage: 9% its preparation technology is identical with embodiment one for Radix Notoginseng 38% Moschus 1% Radix Panacis Quinquefolii 15% Olibanum 11% Myrrha 8% Eupolyphaga Seu Steleophaga 10% Os Draconis 8% Pyritum.
Claims (5)
1, a kind of pharmaceutical composition for the treatment of cardiomyopathy is characterized in that forming by following components in weight percentage: Radix Notoginseng 35-40% Radix Panacis Quinquefolii 15-20% Olibanum 8-12% Myrrha 8-12% Eupolyphaga Seu Steleophaga 8-12% Os Draconis 8-12% Pyritum 8-12% Moschus 1-2%
2, the pharmaceutical composition of treatment cardiomyopathy as claimed in claim 1, it is characterized in that preparing dosage form is capsule.
3, a kind of preparation of drug combination technology of treatment cardiomyopathy as claimed in claim 1 is characterized in that containing following steps:
＜1〉extracts the volatile oil of Olibanum, Myrrha, and fix, collect post-treatment and become extractum standby with β-CD inclusion;＜2〉preparation Eupolyphaga Seu Steleophaga extracting solution is collected post-treatment and is become extractum standby;＜3〉the Os Draconis water soluble ingredient is repeatedly taken and filters, reconcentration becomes extractum standby;＜4〉preparation nature powdered copper concentrate;＜5〉Moschus after prepared extractum, natural powdered copper concentrate and the grinding is mixed and can make with the Radix Notoginseng of sterilization, Western pure extract powder.
4, the preparation of drug combination technology of treatment cardiomyopathy as claimed in claim 3, it is characterized in that described Olibanum, Myrrha extraction process are as follows: Olibanum, Myrrha are ground into granule, do dissolution with solvents and be extracted into the colourless petroleum ether that in the water-bath ventilating kitchen, volatilizees again with petroleum ether, promptly get volatile oil, mixed inclusion with β-CD again and fix.
5, the preparation of drug combination technology of treatment cardiomyopathy as claimed in claim 3, the processing technique that it is characterized in that described Pyritum is: get Pyritum and be popular in being fired to more than 560 ℃, the shortcake of quenching in the impouring rice vinegar immediately then, each about 2 hours for several times so repeatedly, until the gloss complete obiteration, airing is placed on and adds water in the mortar repeatedly and be ground to impalpable powder again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001315161A CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001315161A CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1349812A true CN1349812A (en) | 2002-05-22 |
| CN1156287C CN1156287C (en) | 2004-07-07 |
Family
ID=4594693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001315161A Expired - Fee Related CN1156287C (en) | 2000-10-24 | 2000-10-24 | A pharmaceutical composition for treating myocardial diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1156287C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008539A (en) * | 2010-11-18 | 2011-04-13 | 华侨大学 | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof |
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991665B (en) * | 2010-11-15 | 2012-05-09 | 张景红 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
-
2000
- 2000-10-24 CN CNB001315161A patent/CN1156287C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102008539A (en) * | 2010-11-18 | 2011-04-13 | 华侨大学 | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof |
| CN102008539B (en) * | 2010-11-18 | 2015-02-25 | 华侨大学 | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof |
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
| CN103285104B (en) * | 2013-05-14 | 2016-01-06 | 张景红 | A kind of have the Chinese medicine injection repairing myocardial damage effect |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1156287C (en) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100546615C (en) | Be used for the treatment of Chinese medicine composition of cerebrovascular and preparation method thereof | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN1156287C (en) | A pharmaceutical composition for treating myocardial diseases | |
| CN1173726C (en) | Medicine for curing malignant turnor and its preparation method | |
| CN1310664C (en) | Chinese medicine capsule for treating cardiac and cerebral vascular diseases and its production process | |
| CN105535285A (en) | Chinese herbal preparation with antitumor effect and preparation method and application thereof | |
| CN111617193B (en) | Qinglong stopping particle | |
| CN108057077A (en) | Treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof | |
| CN1840170A (en) | Chinese proprietary medicine for treating cerebral thrombosis | |
| KR20220121247A (en) | Compound preparation for nerve regeneration and method and use thereof | |
| CN106421474A (en) | Formula for traditional Chinese medicines capable of lowering blood lipid | |
| CN101574426B (en) | Chinese patent medicament for treating liver diseases and method for preparing same | |
| CN101991665B (en) | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof | |
| CN105853768B (en) | Traditional Chinese medicine formula for treating rheumatoid arthritis and preparation method and application thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN115177690B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN109602848B (en) | Traditional Chinese medicine composition for treating simple carotid atherosclerotic plaque of middle-aged people | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN106421473A (en) | Preparation method of traditional Chinese medicine capable of reducing blood lipid | |
| CN108175782B (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy | |
| CN105434890A (en) | Radiation stomatitis treating traditional Chinese medicine composition | |
| CN1283303C (en) | Medicine composition for ischemia apoplexy | |
| CN1246030C (en) | Chouxue qing capsule for reducing blood viscosity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040707 Termination date: 20111024 |